Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURV-B2: Surv.m-CRA-1 intratumoral adenoviral therapy in advanced primary malignant bone tumors
jRCT2073250100Not yet recruiting
- Sponsor
- Surv BioPharma
- Start
- Nov 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Surv.m-CRA-1 in bone cancer, sponsored by Surv BioPharma. Primary endpoint: Overall local response by Choi criteria. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
Surv.m-CRA-1
03
Conditions
bone cancer
Beyond the preview
Go deeper on jRCT2073250100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073250100.